These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 27193077)

  • 41. Optimization of Naphthyridones into Selective TATA-Binding Protein Associated Factor 1 (TAF1) Bromodomain Inhibitors.
    Clegg MA; Theodoulou NH; Bamborough P; Chung CW; Craggs PD; Demont EH; Gordon LJ; Liwicki GM; Phillipou A; Tomkinson NCO; Prinjha RK; Humphreys PG
    ACS Med Chem Lett; 2021 Aug; 12(8):1308-1317. PubMed ID: 34413961
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current development of CBP/p300 inhibitors in the last decade.
    He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
    Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis.
    Myrianthopoulos V; Gaboriaud-Kolar N; Tallant C; Hall ML; Grigoriou S; Brownlee PM; Fedorov O; Rogers C; Heidenreich D; Wanior M; Drosos N; Mexia N; Savitsky P; Bagratuni T; Kastritis E; Terpos E; Filippakopoulos P; Müller S; Skaltsounis AL; Downs JA; Knapp S; Mikros E
    J Med Chem; 2016 Oct; 59(19):8787-8803. PubMed ID: 27617704
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of selective inhibitors for cyclic AMP response element-binding protein: a combined ligand and structure-based resources pipeline.
    Muneer I; Ul Qamar MT; Tusleem K; Abdul Rauf S; Hussain HMJ; Siddiqi AR
    Anticancer Drugs; 2019 Apr; 30(4):363-373. PubMed ID: 30499778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain.
    Ferguson FM; Fedorov O; Chaikuad A; Philpott M; Muniz JR; Felletar I; von Delft F; Heightman T; Knapp S; Abell C; Ciulli A
    J Med Chem; 2013 Dec; 56(24):10183-7. PubMed ID: 24304323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CHIPMUNK: A Virtual Synthesizable Small-Molecule Library for Medicinal Chemistry, Exploitable for Protein-Protein Interaction Modulators.
    Humbeck L; Weigang S; Schäfer T; Mutzel P; Koch O
    ChemMedChem; 2018 Mar; 13(6):532-539. PubMed ID: 29392860
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins.
    Yang Y; Wu Z; Chen P; Zheng P; Zhang H; Zhou J
    Future Med Chem; 2020 Sep; 12(18):1669-1683. PubMed ID: 32893690
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Elements of Translational Chemical Biology.
    Copeland RA; Boriack-Sjodin PA
    Cell Chem Biol; 2018 Feb; 25(2):128-134. PubMed ID: 29233521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tailor-made amino acids in the design of small-molecule blockbuster drugs.
    Han J; Konno H; Sato T; Soloshonok VA; Izawa K
    Eur J Med Chem; 2021 Aug; 220():113448. PubMed ID: 33906050
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hot spot-based design of small-molecule inhibitors for protein-protein interactions.
    Guo W; Wisniewski JA; Ji H
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2546-54. PubMed ID: 24751445
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biophysical screening for the discovery of small-molecule ligands.
    Ciulli A
    Methods Mol Biol; 2013; 1008():357-88. PubMed ID: 23729259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
    Brand M; Clayton J; Moroglu M; Schiedel M; Picaud S; Bluck JP; Skwarska A; Bolland H; Chan AKN; Laurin CMC; Scorah AR; See L; Rooney TPC; Andrews KH; Fedorov O; Perell G; Kalra P; Vinh KB; Cortopassi WA; Heitel P; Christensen KE; Cooper RI; Paton RS; Pomerantz WCK; Biggin PC; Hammond EM; Filippakopoulos P; Conway SJ
    J Med Chem; 2021 Jul; 64(14):10102-10123. PubMed ID: 34255515
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeting non-bromodomain chromatin readers.
    Arrowsmith CH; Schapira M
    Nat Struct Mol Biol; 2019 Oct; 26(10):863-869. PubMed ID: 31582844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bromodomain Histone Readers and Cancer.
    Jain AK; Barton MC
    J Mol Biol; 2017 Jun; 429(13):2003-2010. PubMed ID: 27890782
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progress in the Development of non-BET Bromodomain Chemical Probes.
    Theodoulou NH; Tomkinson NC; Prinjha RK; Humphreys PG
    ChemMedChem; 2016 Mar; 11(5):477-87. PubMed ID: 26749027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of an MLLT1/3 YEATS Domain Chemical Probe.
    Moustakim M; Christott T; Monteiro OP; Bennett J; Giroud C; Ward J; Rogers CM; Smith P; Panagakou I; Díaz-Sáez L; Felce SL; Gamble V; Gileadi C; Halidi N; Heidenreich D; Chaikuad A; Knapp S; Huber KVM; Farnie G; Heer J; Manevski N; Poda G; Al-Awar R; Dixon DJ; Brennan PE; Fedorov O
    Angew Chem Int Ed Engl; 2018 Dec; 57(50):16302-16307. PubMed ID: 30288907
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
    Romero FA; Taylor AM; Crawford TD; Tsui V; Côté A; Magnuson S
    J Med Chem; 2016 Feb; 59(4):1271-98. PubMed ID: 26572217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
    Chaikuad A; Lang S; Brennan PE; Temperini C; Fedorov O; Hollander J; Nachane R; Abell C; Müller S; Siegal G; Knapp S
    J Med Chem; 2016 Feb; 59(4):1648-53. PubMed ID: 26731131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.